IL18 and neoplasm: In contrast, treatment with m2G-T + (m)GzB-IL18 T cells significantly reduced tumor progression compared to m2G-T + nil cells (Figure 7G) and did not induce clinically evident toxicity or weight loss (Figure 7H).